EVENT REPLAY NOW AVAILABLE
Recorded December 19, 2023
Press release updated December 14, 2023 to include addition of Dr. Orozco
The event will highlight the isotopes that are the next frontier in radiotherapeutics development, exploring alternatives to industry staples like Lutetium-177 and Actinium-225. Additionally, the discussions will delve into supply chain complexities, the role of CDMOs in bringing radiotherapeutics to patients, and the optimal timing for commercial-scale product development.
Nusano’s production platform enables the creation of rare and hard-to-produce medical radioisotopes in quantities needed for commercial-stage diagnostics and therapeutics. A reliable supply of radioisotopes is an important requirement for drugmakers developing and manufacturing next-generation pharmaceuticals needed to advance the fight against cancer.
A live question and answer session will follow the moderated panel discussion.
Emerging Trends in Radiotherapeutics: Beyond Lu-177 and Ac-225
Format: Panel Discussion
Date: Tuesday, December 19, 2023
Time: 11:00 AM ET
Location: Virtual Event
Register Here
About Suji Jeong, PhD
Suji Jeong, PhD is Founding Partner of The SJR Group, a consulting firm specializing in strategy and CFO services for the radiopharmaceuticals industry. Prior to founding The SJR Group, Suji served as a biotechnology equity research analyst at Jefferies, where she was responsible for covering a diverse range of therapeutic sectors, including radiopharmaceuticals. Suji holds a PhD in neuroscience from Northwestern University and began her biotech equity research career at Morgan Stanley.
About Phil Nicklin
Phil Nicklin is a Senior Analyst at LifeSci Consulting, specializes in evaluating commercial strategies for early-stage biotech and radiopharmaceutical companies with a focus on oncology. He closely tracks all things radiopharmaceuticals, including clinical studies and emerging players in the market. Before joining LifeSci, he worked at Memorial Sloan Kettering Cancer Center, contributing to early-stage clinical trials that encompassed targeted alpha and beta therapies. Phil holds a B.S. in Biological Sciences from Cornell University.
About Dr. Ashley Mishoe, PharmD
Dr. Ashley Mishoe, PharmD, is a nuclear pharmacist and is currently the Vice President of Regulatory Affairs and Quality Assurance at PharmaLogic, where she oversees all regulatory compliance and quality-related aspects for the company’s manufacturing facilities. She previously served as the Director of the Radiopharmaceutical Facility at the University of California, San Francisco. During her tenure there, she oversaw manufacturing operations for clinical and research radiopharmaceuticals. She has held teaching positions within the School of Medicine and School of Pharmacy. Dr. Mishoe earned a Bachelor of Science in Psychology and a Bachelor of Science in Health Sciences, with a minor in music, from Clemson University. She obtained a Doctorate in Pharmacy from the Medical University of South Carolina (MUSC) where she also completed the Authorized Nuclear Pharmacist training certificate and an Interprofessional Education Fellowship. She serves as a member of the United States Pharmacopeia Expert Panel for Small Molecules. She also maintains active memberships in both the American Pharmacists Association and the Society of Nuclear Medicine and Molecular Imaging, where she was selected as the Henkin Government Relations Fellow in 2018. Currently, Dr. Mishoe is involved with numerous committees and councils, including the Radiopharmaceutical Sciences Council, the Government Affairs Committee, the FDA Task Force, the Committee on Radiopharmaceuticals, the Coalition on PET Drugs, and the Medical Imaging and Technology Alliance.
About Dr. Johnnie José Orozco
Dr. Johnnie José Orozco, MD, PhD is a practicing oncologist who studies novel ways to treat blood cancers, and how to make the transplantation of blood-forming stem cells safer and more effective. His research develops radioimmunotherapies that use immune system proteins known as antibodies, stably linked to radionuclides, to selectively target radioactivity to cancer cells, sparing normal tissues. The antibody and its radioactive payload locate and kill tumor cells by damaging their DNA. The goal is to maximize outcomes for cancer patients and minimize off target treatment effects with radioimmunotherapy.
About Nusano, Inc.
Nusano is a privately held medical technology company committed to bringing stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market. Nusano’s proprietary ion source is smaller and more efficient than existing production methods. This results in significantly greater yields and allows for the simultaneous manufacturing of multiple radioisotopes. Nusano’s technologies will supply the fight against cancer and support diagnostic and therapeutic radiopharmaceutical development. The company’s state-of-the-art production facility opens Q1 2025 in West Valley City, Utah. For more, please visit www.nusano.com.
# # #
CONTACTS
Media: Scott Larrivee, Nusano, 608-345-6629, scott.larrivee@nusano.com
Investor Relations: Joyce Allaire, LifeSci Advisors, LLC, 212-915-2569, jallaire@lifesciadvisors.com
